Literature DB >> 15781051

3,4-Methylenedioxymethamphetamine administration on postnatal day 11 in rats increases pituitary-adrenal output and reduces striatal and hippocampal serotonin without altering SERT activity.

Michael T Williams1, Tori L Schaefer, Lisa A Ehrman, Jessica A Able, Gary A Gudelsky, Renu Sah, Charles V Vorhees.   

Abstract

We have previously shown that +/-3,4-methylenedioxymethamphetamine (MDMA) treatment from P11 to P20 in rats produces deficits in cognitive ability when these animals are tested in adulthood. The purpose of this experiment was to explore the neuroendocrine and neurochemical changes produced by MDMA treatment on P11. We examined monoamines in the hippocampus and striatum and the serotonin transporter in the hippocampus as well as pituitary and adrenal output following administration of MDMA (10 mg/kg, 4 times) on postnatal day 11. Significant depletions in serotonin were evident in the hippocampus 1 h and in the striatum 24 h after the first dose and remained reduced 78 h later. No changes in serotonin transporter were observed following MDMA treatment, although females had lower levels than males. No changes in dopamine were detected. The metabolites of serotonin and dopamine had different profiles than the parent compounds after MDMA administration. Plasmatic ACTH was elevated immediately following MDMA and remained elevated for at least 1 h after the last dose and returned to baseline by 24 h. Corticosterone was increased after the first dose and remained increased for at least 24 h, and returned to baseline by 30 h. The decreases in serotonin in regions important for learning and memory in conjunction with elevated levels of corticosterone during a period of stress hyporesponsiveness suggest that these initial responses to MDMA may contribute to the long-term learning and memory deficits following neonatal MDMA exposure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781051      PMCID: PMC2888318          DOI: 10.1016/j.brainres.2005.01.045

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  65 in total

1.  Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity.

Authors:  David Pubill; Anna M Canudas; Mercè Pallàs; Antonio Camins; Jorge Camarasa; Elena Escubedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-09       Impact factor: 3.000

2.  Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain.

Authors:  Paul A T Kelly; Isobel M Ritchie; Linda Quate; Douglas E McBean; Henry J Olverman
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress.

Authors:  Michael T Williams; LaRonda L Morford; Sandra L Wood; Stephanie L Rock; Anne E McCrea; Masao Fukumura; Tanya L Wallace; Harry W Broening; Mary S Moran; Charles V Vorhees
Journal:  Brain Res       Date:  2003-04-04       Impact factor: 3.252

4.  Hippocampal serotonergic damage induced by MDMA (ecstasy): effects on spatial learning.

Authors:  Jon E Sprague; Amanda S Preston; Michael Leifheit; Brian Woodside
Journal:  Physiol Behav       Date:  2003-07

5.  Cognitive strategies dependent on the hippocampus and caudate nucleus in human navigation: variability and change with practice.

Authors:  Giuseppe Iaria; Michael Petrides; Alain Dagher; Bruce Pike; Véronique D Bohbot
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

Review 6.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

7.  The effects of stress exposure on the hypothalamic-pituitary-adrenal axis, thymus, thyroid hormones and glucose levels.

Authors:  Nassia Kioukia-Fougia; Katerina Antoniou; Stathis Bekris; Charis Liapi; Ion Christofidis; Zeta Papadopoulou-Daifoti
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-06       Impact factor: 5.067

8.  Suppression of hippocampal neurogenesis is associated with developmental stage, number of perinatal seizure episodes, and glucocorticosteroid level.

Authors:  H Liu; J Kaur; K Dashtipour; R Kinyamu; C E Ribak; L K Friedman
Journal:  Exp Neurol       Date:  2003-11       Impact factor: 5.330

9.  Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood.

Authors:  Michael T Williams; Tracy L Blankenmeyer; Tori L Schaefer; Carrie A Brown; Gary A Gudelsky; Charles V Vorhees
Journal:  Brain Res Dev Brain Res       Date:  2003-12-30

10.  Influences of the corticotropic axis and sympathetic activity on neurochemical consequences of 3,4-methylenedioxymethamphetamine (MDMA) administration in Fischer 344 rats.

Authors:  Francesca Fernandez; Sylvie Aguerre; Pierre Mormède; Francis Chaouloff
Journal:  Eur J Neurosci       Date:  2002-08       Impact factor: 3.386

View more
  19 in total

Review 1.  Drugs, biogenic amine targets and the developing brain.

Authors:  Aliya L Frederick; Gregg D Stanwood
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

Review 2.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

3.  Treatment with MDMA from P11-20 disrupts spatial learning and path integration learning in adolescent rats but only spatial learning in older rats.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

4.  Ontogeny of the adrenal response to (+)-methamphetamine in neonatal rats: the effect of prior drug exposure.

Authors:  Michael T Williams; Tori L Schaefer; Amy R Furay; Lisa A Ehrman; Charles V Vorhees
Journal:  Stress       Date:  2006-09       Impact factor: 3.493

5.  (+)-Methamphetamine increases corticosterone in plasma and BDNF in brain more than forced swim or isolation in neonatal rats.

Authors:  Curtis E Grace; Tori L Schaefer; Nicole R Herring; Matthew R Skelton; Anne E McCrea; Charles V Vorhees; Michael T Williams
Journal:  Synapse       Date:  2008-02       Impact factor: 2.562

6.  Short- and long-term effects of (+)-methamphetamine and (+/-)-3,4-methylenedioxymethamphetamine on monoamine and corticosterone levels in the neonatal rat following multiple days of treatment.

Authors:  Tori L Schaefer; Matthew R Skelton; Nicole R Herring; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

7.  The role of adenosine receptor agonist and antagonist on Hippocampal MDMA detrimental effects; a structural and behavioral study.

Authors:  Fatemeh Kermanian; Mehdi Mehdizadeh; Mansureh Soleimani; Ali Reza Ebrahimzadeh Bideskan; Majid Asadi-Shekaari; Hamed Kheradmand; Hossein Haghir
Journal:  Metab Brain Dis       Date:  2012-09-09       Impact factor: 3.584

8.  Mouse plasmacytoma-expressed transcript 1 knock out induced 5-HT disruption results in a lack of cognitive deficits and an anxiety phenotype complicated by hypoactivity and defensiveness.

Authors:  T L Schaefer; C V Vorhees; M T Williams
Journal:  Neuroscience       Date:  2009-09-25       Impact factor: 3.590

9.  Neonatal 3,4-methylenedioxymethamphetamine (MDMA) exposure alters neuronal protein kinase A activity, serotonin and dopamine content, and [35S]GTPgammaS binding in adult rats.

Authors:  Cynthia A Crawford; Michael T Williams; Jodie L Kohutek; Fiona Y Choi; Shelly T Yoshida; Sanders A McDougall; Charles V Vorhees
Journal:  Brain Res       Date:  2006-02-14       Impact factor: 3.252

Review 10.  Developmental effects of 3,4-methylenedioxymethamphetamine: a review.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Behav Pharmacol       Date:  2008-03       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.